The evidence leans constructive5 supporting, 2 against, 1 worth knowing
Supporting
trading 17% above its 200-day average
matches stretched far above trend, which has beaten the market by +0.82 points over 20 sessions across 27,715 past signals
7 independent kinds of evidence agree today, which is uncommon
revenue grew 44% year on year in the quarter ending 2026-06-30
net margin has widened from 10.2% to 19.8% across four quarters
Against
down 5% over twelve months
2 of the scans it matches have historically underperformed the market
Worth knowing
RSI at 76 is stretched; strong stocks stay stretched for a long time, so this is a note on entry timing, not on direction
What would change this read: a close below 14, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Net profit +123.7% year on year, Rs 11 cr to Rs 25 cr.
+123.7%Rs 11 crRs 25 cr
Profit grew faster than revenue, +123.7% against +22.7%.
+123.7%+22.7%
Net margin moved from 10.9% to 19.8%.
10.9%19.8%
Needs watching1
Pharmaceuticals Drugs & formulations is 99% of revenue, so the business rests on one segment.
Pharmaceuticals Drugs & formulations99%
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
14 of 47 matched on 2026-08-21
SYNCOMF matches 14 of the 47 scans today, across 7 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
segments and revenue mix, as the company reports them
SYNCOMF reports 3 business segments. The largest is Pharmaceuticals Drugs & formulations at 99% of revenue in the quarter ending 2026-06-30. On these numbers this is effectively a single-segment business, so the group result and that segment’s result move together.
SegmentRevenueSharevs a year ago
Pharmaceuticals Drugs & formulations132 cr99.2%—
Renting of Property1 cr0.6%—
Trading of Commodities0 cr0.2%—
Segment names are the company’s own, taken verbatim from the reportable-segment disclosure in its quarterly XBRL filing. Nothing on this page describes the business in words we wrote.
Quality of the business
balance sheet as at 2026-03-31
Return on equity
19.7%
trailing profit over shareholders’ funds
Return on capital
26.0%
pre-tax profit over equity plus borrowings
Debt to equity
0.00×
1 cr borrowed against 415 cr of equity
Net debt
4 cr
cash exceeds borrowings
Cash conversion
71%
operating cash flow as a share of profit
Receivable days
80
how long customers take to pay
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
500 sessions since 2024-09-06
19×
median 40×
70×
now 19×
SYNCOMF trades at 19× trailing earnings, below its median of 40× over this window — 54% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362) · Management filings were typically -0.01pt vs the market over the next 5 sessions (n=1,988)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 44% against the same quarter a year earlier
profit rose 226% year on year
net margin widened from 18.6% to 19.8%
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
126
32
25
0.26
19.8%
Q4 FY26
2026-03-31 · consolidated
135
34
25
0.27
18.6%
Q3 FY26
2025-12-31 · consolidated
115
25
19
0.23
16.4%
Q3 FY25
2024-12-31 · consolidated
128
17
13
0.14
10.2%
Q2 FY25
2024-09-30 · consolidated
102
15
11
0.16
10.9%
Q1 FY25
2024-06-30 · consolidated
87
10
8
0.11
8.7%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+15.1%
Versus 200-day average+17.3%
Below 52-week high-10.7%
Above 52-week low+56.7%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)76.1
Higher closes in last 54 of 5
Six-month return+25.51%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.